Daily desk

News

Artificial intelligence, technology, science, health and education — reported daily, with the original source attached to every item.

6 item(s)

A stylized bacteriophage docking on a drug-resistant bacterium illustrates the new consensus guideline, backed by stats on its 60+ recommendations, 20 organizations and 18 expert authors.
🩺 Health Report

First International Consensus Guideline for Personalized Phage Therapy Published in Nature Medicine

An international working group coordinated by Germany's DGI has published the first consensus guideline for personalized bacteriophage ther…

EduFabTech · 10h ago · 4 min read
A single AAV gene-therapy infusion cut annualized bleeding from 13.9 to 0.5 episodes per year in 11 adolescents with hemophilia B, restoring liver production of factor IX.
🩺 Health Study

Gene Therapy Cuts Bleeding Episodes in Adolescents With Hemophilia B, Small Phase 1 Trial Finds

A phase 1 trial in Nature Medicine found that a single AAV gene therapy infusion cut bleeding episodes in 11 adolescents with hemophilia B,…

EduFabTech · 4d ago · 4 min read
A brainstem diagram highlights where diffuse midline glioma forms, alongside survival figures for children taking the epilepsy drug levetiracetam versus those who were not.
🩺 Health Study

A Common Epilepsy Drug Is Linked to Longer Survival in an Almost Untreatable Childhood Brain Tumor

A retrospective Nature Medicine study (Sept. 17, 2026) led by Stanford Medicine finds children with diffuse midline glioma survived longer …

EduFabTech · 6d ago · 4 min read
A blood-drop icon holding ten microRNA markers plus CA19-9 illustrates the PANXEON score, alongside its 86.8% stage I-II sensitivity, 96.8% specificity, and 1,785-patient cohort.
🩺 Health Study

A Blood-Based Score Combining Ten microRNAs and CA19-9 Flags Early Pancreatic Cancer in a 1,785-Person Study

A prospective 1,785-person study published in Nature Medicine on September 16, 2026, found that PANXEON — a blood test combining ten microR…

EduFabTech · 17 Sep 2026 · 4 min read
A CD3×CD19 bispecific antibody bridges a patient's T cell and a B cell, with key trial results — 12 patients, 80% reaching low disease activity, 60% meeting remission criteria.
🩺 Health Study

Phase 1 Trial Finds a Cancer-Style T-Cell Engager Can Push Refractory Lupus Into Remission

A phase 1 trial of A-319, a CD3×CD19 bispecific antibody adapted from cancer therapy, pushed most of 12 treatment-resistant lupus patients …

EduFabTech · 16 Sep 2026 · 4 min read
A bispecific antibody schematic bridges a T-cell and a myeloma cell, alongside headline stats showing 77.8% complete response, 92% two-year progression-free survival, and a hazard ratio of 0.15 for teclistamab.
🩺 Health Study

Randomized Trial Finds Teclistamab Outperforms Standard Early Treatment in High-Risk Smoldering Myeloma

A phase 2 trial in Nature Medicine found that early teclistamab treatment produced deep, durable remissions in high-risk smoldering myeloma…

EduFabTech · 15 Sep 2026 · 4 min read